Literature DB >> 11917903

Salvaging the ischaemic penumbra: more than just reperfusion?

Thanh G Phan1, Peter M Wright, Romesh Markus, David W Howells, Stephen M Davis, Geoffrey A Donnan.   

Abstract

1. The ischaemic penumbra is defined as a moderately hypoperfused region that retains structural integrity but has lost function. In animal models of ischaemic stroke, this region is prone to recurrent anoxic depolarization and will become infarcted if reperfusion does not occur. In the macaque model, an ischaemic penumbra has been identified for up to 3 h after ischaemic stroke onset, whereas in selected human patients it may exist for up to 48 h. 2. Although most definitions of the ischaemic penumbra stress a time-brain volume concept, few incorporate the idea that selective and delayed neuronal injury plays an important role. Thus, in addition to necrotic cell death caused by acute injury, it is important to also consider delayed death mediated by caspase-dependent and -independent apoptotic pathways. 3. Salvage of penumbral tissue is possible if reperfusion (e.g. after thrombolysis) occurs. However, neurons within this salvaged region may be still at risk of further delayed neuronal injury. 4. In the present review, we aim to revisit the concept of the ischaemic penumbra and explore the role of selective and delayed neuronal injury in enlargement of the volume of infarction, as well as pathogenic mechanisms of white matter ischaemia. Both animal and human models of cerebral ischaemia imaged using magnetic resonance and positron emission tomography techniques will be discussed.

Entities:  

Mesh:

Year:  2002        PMID: 11917903     DOI: 10.1046/j.1440-1681.2002.03609.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  22 in total

1.  [Multimodal computed tomography in acute cerebral infarction. Experience with a standardized protocol in 100 patients].

Authors:  R Handschu; S Fateh-Moghadam; E Klotz; A Schmid; B Stemper; J G Heckmann; W J Huk; B Neundörfer; B F Tomandl
Journal:  Nervenarzt       Date:  2004-06       Impact factor: 1.214

2.  Critical early thrombolytic and endovascular reperfusion therapy for acute ischemic stroke victims: a call for adjunct neuroprotection.

Authors:  Paul A Lapchak
Journal:  Transl Stroke Res       Date:  2015-08-29       Impact factor: 6.829

Review 3.  Neuroprotection for ischemic stroke using hypothermia.

Authors:  Angelos-Aristeidis Konstas; Jae H Choi; John Pile-Spellman
Journal:  Neurocrit Care       Date:  2006       Impact factor: 3.210

4.  Changes in gene expression in the rat hippocampus after focal cerebral ischemia.

Authors:  Jun Young Chung; Jae Woo Yi; Sung Min Kim; Young Jin Lim; Joo Ho Chung; Dae Jean Jo
Journal:  J Korean Neurosurg Soc       Date:  2011-09-30

5.  Intra-arterial treatment of acute ischemic stroke: the continued evolution.

Authors:  Alex Y Lu; Sameer A Ansari; Karin V Nyström; Eyiyemisi C Damisah; Hardik P Amin; Charles C Matouk; Rashmi D Pashankar; Ketan R Bulsara
Journal:  Curr Treat Options Cardiovasc Med       Date:  2014-02

6.  Sustained (S)-roscovitine delivery promotes neuroprotection associated with functional recovery and decrease in brain edema in a randomized blind focal cerebral ischemia study.

Authors:  Estelle Rousselet; Anne Létondor; Bénédicte Menn; Yann Courbebaisse; Marie-Lise Quillé; Serge Timsit
Journal:  J Cereb Blood Flow Metab       Date:  2017-06-01       Impact factor: 6.200

7.  Piperphentonamine (PPTA) attenuated cerebral ischemia-induced memory deficits via neuroprotection associated with anti-apoptotic activity.

Authors:  Juan Bin; Qian Wang; Ye-Ye Zhuo; Jiang-Ping Xu; Han-Ting Zhang
Journal:  Metab Brain Dis       Date:  2012-07-29       Impact factor: 3.584

8.  Protein kinase C delta mediates cerebral reperfusion injury in vivo.

Authors:  Rachel Bright; Ami P Raval; Jeffrey M Dembner; Miguel A Pérez-Pinzón; Gary K Steinberg; Midori A Yenari; Daria Mochly-Rosen
Journal:  J Neurosci       Date:  2004-08-04       Impact factor: 6.167

9.  Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models.

Authors:  Bénédicte Menn; Stéphane Bach; Teri L Blevins; Mark Campbell; Laurent Meijer; Serge Timsit
Journal:  PLoS One       Date:  2010-08-12       Impact factor: 3.240

10.  Neuroprotective effects of adenosine deaminase in the striatum.

Authors:  Risa Tamura; Hiroyuki Ohta; Yasushi Satoh; Shigeaki Nonoyama; Yasuhiro Nishida; Masashi Nibuya
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-08       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.